8th Annual Generic Drugs Summit

Online registration is open!

Thanks to all of our event sponsors, for their contributions to this event!

Thanks to all of our event Media Partners, for their contributions to this event!

Have a question about this event?
Customer Service representatives are available to help from 8 AM - 6 PM EST
Call 888-670-8200

Need Technical Assistance With this Website?
Send an email to IIR's Web Department

September 17 - 19, 2007 | The Fairmont, Washington , DC

MAIN CONFERENCE DAY TWO: WEDNESDAY, SEPTEMBER 19, 2007

8:00	Morning Coffee
8:15	Chairperson's Opening Remarks & Recap of Day One
SENATORIAL ADDRESS
8:30	Lower Priced Drugs Act: Removing Hurdles that Slow Affordable Generics from Coming to Market The Honorable Debbie A. Stabenow (D-MI). US SENATE
WALL STREET ADDRESS
9:15	Changes, Opportunity and Outlook for the Generics Industry Randall Stanicky, Vice President, Global Investment Research, GOLDMAN SACHS
10:00	Morning Refreshment and Networking Break
EXECUTIVE ROUNDTABLE
10:30	The Changing Competitive Landscape of the Generic Drugs Industry Moderator: Vijay Karwal, Director Healthcare, ABN AMRO Panelists: Christopher Mengler, R.Ph., Senior Vice President, Corporate Development, BARR LABORATORIES Jeffrey Yordon,CEO, SAGENT PHARMACEUTICALS Arthur Bedrosian, President & CEO, LANNETT Lalit Ahluwalia, CFO, RANBAXY PHARMACEUTICALS
11:30	Up-to-the-Minute Analysis of Court Decisions Affecting the Generic Drug Industry Jordan A. Sigale, Partner, LOEB & LOEB
12:15	Luncheon for Delegates and Speakers

Concurrent Tracks Begin

	Track A: Intellectual Property & Legal Issues	Track B: Business Trends & Strategy
1:30	Why the Odds Are Better For Winning a Chemical Obviousness Argument Shannon Mrksich, PhD, Shareholder, BRINKS HOFER GILSON & LIONE	Business Perspectives: Challenges and Opportunities in India
2:15	Inequitable Conduct - Strategies for Invalidating The Branded Pharma Patents Brian D. Coggio, Shareholder, GREENBERG TRAURIG	505(b)(2): Risks and Rewards of Generic Innovation Nicholas M. Fleischer, RPh, PhD, Vice President, Clinical Pharmacology & Biopharmaceutics, THE WEINBERG GROUP INC
3:00	Conference Concludes